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Abstract
To optimize malaria control, WHO has prioritised the need for new indicators to evaluate the efficacy of malaria vector
control strategies. The gSG6-P1 peptide from gSG6 protein of Anopheles gambiae salivary glands was previously designed as
a specific salivary sequence of malaria vector species. It was shown that the quantification of human antibody (Ab)
responses to Anopheles salivary proteins in general and especially to the gSG6-P1 peptide was a pertinent biomarker of
human exposure to Anopheles. The present objective was to validate this indicator in the evaluation of the efficacy of
Insecticide Treated Nets (ITNs). A longitudinal evaluation, including parasitological, entomological and immunological
assessments, was conducted on children and adults from a malaria-endemic area before and after the introduction of ITNs.
Significant decrease of anti-gSG6-P1 IgG response was observed just after the efficient ITNs use. Interestingly, specific IgG
Ab level was especially pertinent to evaluate a short-time period of ITNs efficacy and at individual level. However, specific
IgG rose back up within four months as correct ITN use waned. IgG responses to one salivary peptide could constitute a
reliable biomarker for the evaluation of ITN efficacy, at short- and long-term use, and provide a valuable tool in malaria
vector control based on a real measurement of human-vector contact.
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Introduction
Vector-borne diseases constitute major public health problems
in developing countries and currently present high risks of re-
emergence in the developed world. Developing tools for disease
control is a priority, especially new anti-vector strategies to prevent
transmission. Among these diseases, malaria represents the
greatest worldwide problem, causing at least 400 million acute
cases every year with around 1 million deaths [1]. Most of these
deaths occur in children from Sub-Saharan Africa and are due to
Plasmodium falciparum species. In these areas, the Anopheles gambiae
complex is the major vector [2].
Preventive methods are used against both parasite (chemopro-
phylaxis) and vector (insecticide-based control). Among anti-vector
strategies, Insecticide Treated Nets (ITNs) are currently the most
efficient strategy for reducing human exposure to the vector,
Plasmodium transmission and malaria morbidity [3,4,5]. When
correctly used, even moderate coverage of populations (35–65%)
can afford substantial community benefit as well as personal
protection [6,7,8,9]. Moreover, implementation of Long-Lasting
Insecticidal Nets (LLINs) represents an achievable means of
rapidly improving ITN coverage [10]. The evaluation of ITN
efficacy is currently based on entomological methods (entomolog-
ical inoculation rate, Anopheles abundance and agressivity) and, in
humans, on parasitological and clinical assessments [4,11,12]. The
reference WHO method for phase 3 evaluation of ITNs efficacy is
based on the measurement of P. falciparum density in human
populations [12]. However, these methods present limitations
when it comes to large-scale field studies, especially when
transmission rates and exposure levels are low (dry season, high
altitude, urban settings or after vector control). Moreover,
evaluating Plasmodium density in human individuals is labour-
intensive by active follow-up of populations. Entomological
methods are mainly applicable at the population/area level and
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in a given area. Human-landing catch measurements (adult
volunteers) are currently the reference method for evaluating
individual human exposure but it raises ethical questions and it
may not be relevant to children [13]. In addition, as exposure
levels drop with ITNs use, all these monitoring methods become
less effective for evaluation by National Malaria Control Programs
[14].
In order to improve vector control, much effort is being devoted
to developing new indicators to evaluate, at the individual level,
the efficacy of control strategies. One promising approach is based
on the idea that exposure to arthropod vector bites can be assessed
by directly measuring real human-vector contact. Indeed, the
human antibody (Ab) response to arthropod salivary proteins
could give a measure of exposure to vector bites [15,16]. At the
time of biting, the female mosquito injects saliva containing
bioactive molecules which facilitate the blood meal and some of
these are antigenic [17,18,19]. Human Ab responses to the saliva
of various vectors, e.g. Triatoma (Chagas’ disease) [20], Ixodes ticks
(Borrelia) [21,22], phlebotomes (Leishmania) [23,24] and Glossina
(African trypanosomiasis) [25] have been reported as reliable
immunological markers for vector exposure. For mosquitoes, anti-
saliva Ab responses has been related to exposure to Culex, Aedes
[26,27,28,29], An. gambiae [30], An. dirus [31] and An. darlingi [32].
Recently, it has been shown that the Ab response to whole An.
gambiae saliva could be a useful biomarker for evaluating ITN
efficacy in phase 3 studies [33]. Even if this concept may appear to
be valid, whole vector saliva could not be used, as pertinent
indicator, because of i) potential cross-reactivity with salivary
epitopes of other hematophagous arthropods; ii) lack of reproduc-
ibility between saliva batches and iii) the adequate production
needed for large-scale studies. For use as a biomarker for Anopheles
exposure, the specific [34,35] and antigenic [36] Anopheles SG6
salivary protein has been identified as an encouraging candidate
[37]. The gSG6 protein, first identified in An. gambiae [38], was
further reported as being highly conserved among Anopheles species
[39,40]. To optimize this biomarker candidate, peptide design has
recently been applied using bioinformatics approach to generate
five Anopheles specific peptides (gSG6-P1 to gSG6-P5). Among
them, only the gSG6-P1 peptide was validated as a specific
biomarker of exposure to malaria vectors. Indeed, the level of
human IgG to gSG6-P1 peptide evaluated the level of exposure to
An. gambiae bites in human populations from a rural area in
Senegal [37]. IgG response to this peptide has been also confirmed
as biomarker for evaluating very low-level exposure to An. gambiae
[41] as well as An. funestus (the second major malaria vector in
Africa) [42]. In addition, the gSG6-P1 peptide can be easily
synthesized in large quantity and offers an efficient solution to the
lack of reproducibility observed with whole salivary extracts [37].
The present study addresses a potentially important application
of such biomarker as a tool to evaluate the efficacy of ITN-based
strategies. Human IgG responses to the gSG6-P1 peptide were
evaluated before and after the introduction of ITNs in individuals
living in a malaria-endemic area. The results focused on the
biomarker’s potential for evaluating short-term ITN efficacy.
Materials and Methods
Ethics Statement
This study was conducted in accordance with the Edinburgh
revision of the Helsinki Declaration, and was approved by the
National Malaria Control Program of the Ministry of Health of
Angola (October 17th 2008), the only one Ethical authority in
2008 for approving studies on malaria research in Angola. Written
informed consent (signed by the head of each household) was
obtained for all individuals enrolled in the study, by the
SONAMET Malaria Control Program (MCP) which supervise/
control malaria infection of all workers for SONAMET and their
family. This consent procedure was regularly approved by
SONAMET workers, beneficing from several malaria studies/
survey by MCP, and was approved by the involved Ethical
authority in Angola.
Study population
This study was conducted in Lobito, a coastal city of Western
Angola, from March 2005 to January 2007. The site is in the
tropical savannah with a rainy season from October to May, with
approximately 600–700 millimetres of rain per year. The duration
of the malaria transmission season varies between 7 and 12
months with a peak between March and May. The major malaria
vector is here the An. gambiae s.l. complex [43,44].
The population has been previously described [33]. Briefly, all
workers of the SONAMET company lived in 250 households.
Residents of these households were followed in the SONAMET
in-patient clinic. In 2004, the presence of malaria parasite was
diagnosed in sixty (60) households (positive, at least, in one
member of household) by SONAMET Malaria Control Program
(MCP). Twenty-one (21) of these 60 households were then
randomly selected for the present study. These families lived in
the Bella Vista district where exposure to An. gambiae s.l bites was
relatively uniform. All residents of the 21 selected households,
corresponding to two hundred and fifty (250) individuals (children
and adults), were included for longitudinal follow-up, with
evaluations every 6 weeks from March 2005 to January 2006
(before ITNs), and from April 2006 to January 2007 (after ITNs).
The families were given LLIN treated with deltamethrin
(PermanetH) in February 2006 (according to the number of rooms
and beds per household). At each visit, samples were collected
from each individual: thick blood smears for parasitological
measurements and dried blood spots (on filter paper) for
immunological analysis. Parasite density (parasitaemia) was
calculated as the number of P. falciparum parasites per microliter
of blood; mean parasitaemia values (x+1) were calculated [33].
Immunological tests were performed in a sub-sample (n=105,
children and adults) of the whole study population (n=230).
Individuals who missed more than 2 of the 14 visits (travel, illness,
change of household,…) were excluded from the immunological
assessments as described previously [33]. Filter papers were kept at
+4uC in Silicagel before testing.
Entomological analysis and survey of ITN use
Mosquitoes were collected every six weeks during the study
period at 6 reference households, representative of the studied
area. An. gambiae density was evaluated using capture by CDC
miniature light traps, deployed from 19:00 hours to 07:00 hours
for two consecutive nights. PCR was used to confirm species to
yield an estimate of the number of An. gambiae/trap/night.
After the introduction of ITNs, their use by individuals and their
quality were inspected, the night before each blood sampling, by
the MCP team. Information were then collected for all studied
individuals by questionnaires, covering: i) the number of installed
ITNs, ii) the number of exchanged ITNs and iii) the number of
damaged ITNs (hole, torn, etc.), as previously described [33].
Salivary gSG6-P1 peptide
The gSG6-P1 peptide was designed as previously described
[37], synthesized and purified (.95%) by Genepep SA (St-
Cle ´ment de Rivie `re, France). All peptide batches were shipped in
New Salivary Biomarker for ITN Efficacy
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water and frozen at 280uC until their use.
Evaluation of human IgG antibody levels (ELISA)
Standardized dried blood spots (1 cm diameter) were eluted by
incubation in 300 ml of phosphate buffered saline (PBS–Tween-
0.1%) at 4uC for 24 hours [33]. ELISAs were carried out on
eluates to assay IgG to the gSG6-P1 antigen. Maxisorp plates
(Nunc, Roskilde, Denmark) were coated with gSG6-P1 (20 mg/
mL) in PBS. Each eluate was then incubated (duplicate) at 4uC
overnight at a 1/20 dilution (PBS–Tween-1%). This optimal
dilution had been determined in preliminary experiments. Mouse
biotinylated Ab against human IgG (BD Pharmingen, San Diego,
CA, USA) was incubated at a 1/2000 dilution and peroxidase-
conjugated streptavidin (Amersham, Les Ulis, France) was then
added (1/2000) Colorimetric development was carried out using
ABTS (2,2’-azino-bis (3-ethylbenzthiazoline 6-sulfonic acid) dia-
mmonium; Sigma, St Louis, MO) in 50 mM citrate buffer (pH 4)
containing 0.003% H2O2. Optical Density (OD) was measured at
405 nm. In parallel, each test sample was assessed in a blank well
containing no gSG6-P1 antigen (ODn) to measure non-specific
reactions. Individual results were expressed as the DOD value:
DOD=ODx-ODn, where ODx represents the mean of individual
OD in both antigen wells. Specific anti-gSG6-P1 IgG levels were
also assayed in non-Anopheles exposed individuals (n=14 – neg;
North of France) in order to quantify the non-specific background
Ab level and to calculate the specific immune response threshold
(TR): TR= mean (DDOneg)+3SD=0.204, i.e. an exposed
individual was classified as a responder if its DOD.0.204.
Statistical analysis
All data were analyzed with GraphPad Prism4 softwareH (San
Diego,CA, USA). After checking the non-Gaussian distribution,
the non-parametric Mann-Whitney U-test was used to compare
Ab levels between two independent groups, the Wilcoxon matched
pairs test was used for comparison between two paired groups, the
non-parametric Kruskal-Wallis test for comparisons between more
than two groups and the Chi-2 test to compare two proportions.
All differences were considered significant at P,0.05.
Results
Anti-gSG6-P1 IgG responses before and after ITN use
The evolution of the percentage of ‘‘immune responders’’
(Fig. 1A) and the levels of anti-gSG6-P1 IgG Abs (Fig. 1B) were
evaluated before (March 2005 to January 2006) and after (April
2006 to January 2007) the installation of ITNs (February 2006).
Before the introduction of ITNs, the percentage of anti-gSG6-
P1 IgG responders appeared relatively constant according to
months (64 to 81%) (Fig. 1A). Within two months of the ITNs
introduction (April. 2006), the percentage of immune responders
had decreased significantly (P,0.0001) down to 5% from 64% in
January 2006. In parallel, the density of An. gambiae (classical
entomological methods) and the intensity of P. falciparum infection
(mean parasitaemia) are shown for the same period (Fig. 1A).
Whereas peak of parasitaemia was observed in May 2005, only
low-level infection was observed after the introduction of ITNs
(2006). In particular, parasitaemia was lower in April 2006
compared to May 2005, which suggests that ITNs were effective,
as previously described [33]. In addition, the densities of An.
gambiae peaked in May 2005 with a small rise from October 2005.
After the introduction of ITNs, a similar peak was observed (April
to July 2006), indicating that entomological exposure was
comparable in 2006 to that in 2005 in the studied area.
A similar trend was observed in the percentage of immune
responders (Fig. 1A) and specific IgG Ab levels (Fig. 1B). In spite of
inter-individual heterogeneity, the anti-gSG6-P1 IgG level was
strong and relatively stable before the introduction of ITNs
(Fig. 1B) although small but significant seasonal variations were
seen in median specific IgG levels (P,0.0001). The major peak of
Ab level was detected in May 2005, as observed for both
entomological An. gambiae exposure and P. falciparum density
(Fig. 1A). Immediately after the introduction of ITNs, a marked
decrease in anti-gSG6-P1 IgG was observed between April and
October 2006. Specific IgG levels were markedly lower in 2006
than in 2005 in June-July (P,0.001), August (P,0.001) and
October (P,0.001). Interestingly, the greatest drop in Ab levels
was observed in all individuals just two months after ITN
introduction in April 2006, the month corresponding to the peak
anti-IgG level before ITNs (P,0.001 for April 2006 compared to
March-April 2005 and P,0.0001 for April 2006 compared to
May 2005). The still positive Ab responses to gSG6-P1 (Fig. 1B)
just after ITN installation (April and June-July 2006) were almost
exclusively observed in older children and adults: the 5 responders
in April 2006 and 15/16 responders in June-July 2006 were from
7-14 and .14 years age groups.
The percentage of specific immune responders (Fig. 1A) and the
level of anti-gSG6-P1 IgG Ab (Fig. 1B) increased significantly in
October 2006 compared to August 2006 (P,0.001) to reach a
high level in December 2006 and January 2007, similar to that
observed before ITN introduction in 2005. Interestingly, the major
results of the ITN survey (loss rate and correct/damaged-usage
rate) evaluated by two horizontal surveys (April and June/July
2006) indicated that: i) after just 4 months (June/July), only 63% of
the ITNs were installed, and ii) only 53% were being used
correctly (in use and undamaged), as previously described in detail
[33].
Individual IgG responses to gSG6-P1 and short-term ITN
efficacy
Previous analyses have been performed at the population level.
To investigate changes in anti-gSG6-P1 IgG levels as a biomarker
at the individual level and immediately after ITN installation, IgG
level was individually evaluated just before (January 2006) and just
after (April 2006) the introduction of ITNs (Figure 2). For almost
all individuals, specific IgG levels decreased significantly in April
2006 compared to January 2006 (P,0.0001 – Fig. 2A). Other
patterns - an increase or no change - were observed in only 5% of
individuals. In addition, a new indicator of the January/April
difference in IgG level was defined (DODITNs=DODApril -
DODJanuary) to assess individual trends (positive, negative or
unchanged) between both months (Fig. 2B). After applying a
threshold for positive IgG response (DOD.0.204), 60% of
individuals showed a decrease (DODITNs ,-0.204) whereas only
1% showed an increase (DODITNs .0.204) and 39% (39/100)
showed no significant change (-0.204,DODITNs ,+0.204).
Changes in anti-gSG6-P1 IgG responses according to age
The changes in anti-gSG6-P1 IgG level was analysed (Figure 3)
according to age of individuals in 3 age groups: 0–6 (n=49), 7–14
(n=34) and .14 years (n=25). Similar trends in all age groups
were observed between 2005 and 2006 (Fig. 3A), in particular a
substantial drop in April 2006 after the introduction of ITNs.
Nevertheless, there are significant age-related differences in some
months, e.g. during the peaks before ITN introduction (May and
October 2005) and in June-July 2006, where anti-gSG6-P1 IgG
levels were significantly higher in older-children and adults (.14
New Salivary Biomarker for ITN Efficacy
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15596Figure 1. IgG Ab responses to gSG6-P1 before and after ITN use. The percentage (%) of anti-gSG6-P1 IgG immune responders (thick-dotted
line) in the ‘‘immunological’’ sub-population (n=105), before (2005) and after (2006 and January 2007) the installation of ITNs (A). These results are
presented together with the intensity of P. falciparum infection (mean parasitaemia – fine-dotted line) measured in the same population and the
New Salivary Biomarker for ITN Efficacy
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seasonal variations were most marked in the .14 years age group.
The relationship between short-term ITN efficacy and anti-
gSG6-P1 IgG levels was analysed according to age group (Figure 3
B, C and D). A marked decrease was observed between January
and April 2006 in all age groups. In particular, IgG level decreased
clearly in all young children from 0–6 years (Fig. 3B) whereas some
individuals of 7–14 years (Fig. 3C) and .14 years (Fig. 3D)
presented increased or unchanged Ab responses.
Discussion
This study focused on the application of a new biomarker based
on evaluation of the human Ab response to an Anopheles salivary
peptide, as an indicator for evaluating the efficacy of malaria
vector control. In this study, a step-by-step approach was adopted
to validate the anti-gSG6-P1 IgG response as a biomarker for ITN
efficacy from the whole population level to the individual level
with a view to identifying a potential tool for evaluation
immediately after the introduction of ITNs.
Firstly, the present study and previous data [33] indicated that
the correct use of deltamethrin ITNs was followed by a
considerable decrease of P. falciparum parasitaemia, the current
WHO criterion for vector control efficacy [13]. It indicated that
ITNs installation was short-term effective in the studied popula-
tion. In the whole population, the percentage of immune
responders and the level of anti-gSG6-P1 IgG Ab in most
individuals decreased considerably just after ITNs introduction
(April-October 2006). The drop was particularly marked in April-
August 2006, corresponding to the peak of An. gambiae exposure.
Interestingly, the entomological data indicated that this season-
dependent peak was similar before (2005) and after (2006) ITN
use. This suggests that ITN installation had no impact on An.
gambiae density, probably because of the low percentage of the
overall population covered in the studied area [45]. It indicated
also that the drop of anti-gSG6-P1 IgG response was associated
with correct ITN use and not due to low Anopheles density. As
described [37,41], Ab responses to gSG6-P1-peptide could
accurately reflect human-vector contact. A marked drop after
ITN installation was observed in all age groups studied (,7 years,
7–14 years, and .14 years) suggesting that this biomarker is
relevant for ITN evaluation in all age groups. Taken together,
these results confirm that - as previously shown with whole An.
gambiae saliva [33] - the estimation of human Ab responses to
Anopheles salivary proteins could provide a reliable biomarker for
evaluating the efficacy of malaria vector control. It validates the
general approach to use Ab to salivary antigens for evaluating the
quantitative human exposure to mosquito bites.
The specific gSG6-P1 peptide is more reliable than whole saliva
which may show cross-reactivity with salivary epitopes from other
arthropods and which could skew and/or overestimated described
effects [37]. Interestingly, compared to IgG responses to whole
saliva [33], the percentage of responders and the levels of anti-
gSG6P1 IgG showed less variability before ITN installation (2005)
and especially remained high in January 2006, one month before
ITN installation. The use of gSG6-P1 peptide increases the
sensitivity and the specificity of such type of biomarker. It
strengthens such effective peptide biomarker for the evaluation of
ITN efficacy at a large scale. The smallness of seasonal variations
could preclude the need for demanding longitudinal evaluation as
needed for parasitaemia indicator (full year before introduction
and especially during the peak of transmission). One measurement
of anti-gSG6-P1 Ab just before ITN installation could provide a
representative picture of the specific Ab response, i. e. exposure
level to Anopheles, prior to ITN introduction.
The gSG6 peptides were designed on the basis of the An. gambiae
s.s. sequence, the only Anopheles genome completely available [46].
In the studied area, the An. gambiae s.l. complex, especially An.
gambiae s. s., is the main vector of P. falciparum as previously
described [44]. However other Anopheles species, such as An.
arabiensis and An. melas, were locally caught in the study area and
had been reported to participate to malaria transmission as
Figure 2. IgG response to gSG6-P1 as biomarker for short-term ITN efficacy. Changes in individual IgG levels (DOD) are presented between
‘‘just before’’ (January 2006) and ‘‘just after’’ (April 2006) ITN introduction (n=105; children and adults) (A). The arrow indicates the installation of
Insecticide Treated Nets (ITNs) in February 2006. Individual IgG level changes from January (before) to April are presented (B) by individual DODITNs,
value (DODITNs=DODApril06,-DODJanuary06). The threshold of specific IgG responders (TR=0.204) is indicated (dotted line). Significant positive
(DOD.0.204) or negative (DOD,20.204) changes are therefore individually presented.
doi:10.1371/journal.pone.0015596.g002
mean of number of An. gambiae (solid line) in the studied area (A). Entomological data (number of An. gambiae) were not available in December 2006
and January 2007 (the two last months of the study). This arrow indicates the installation of Insecticide Treated Nets (ITNs) in February 2006.
Individual anti-gSG6-P1 IgG levels (DOD) are presented before (2005) and after (2006) the installation of ITNs (B). Bars indicate the median value for
each studied month. Statistically significant differences between months are indicated.
doi:10.1371/journal.pone.0015596.g001
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‘‘secondary’’ Anopheles species have been probably evaluated using
gSG6-P1 peptide which presents a very stable domain of the gSG6
Anopheles salivary protein [37] and monoacids sequences highly
conserved among Anopheles species [40]. For example, it has been
shown that gSG6-P1 peptide shares 82% and 91% identity with
An. stephensi and An. funestus [37] and that IgG response to this
peptide was also biomarker of An. funestus exposure [42]. All these
data tends to support the idea that gSG6-P1 can be used to
evaluate the exposure to major Anopheles species known to be
vector of malaria.
After an analysis at the whole population level, an ideal
biomarker has to be used i) at the individual level and ii) to
evaluate short-term ITN efficacy. The individual results showed
that few individuals presented a positive anti-gSG6-P1 IgG
response just after ITN installation (from April to August 2006)
and that most of these were older children or adults (.14 years). It
cannot be ruled out that these older individuals may stay outside
the house until late in the evening when Anopheles starts biting
again so they therefore derive less protection from ITNs than
young children who go to sleep earlier in the evening. Individual
specific IgG response between January (before) and April 2006 (2
months after ITNs) showed a considerable decrease in all age
groups. This rapid decrease after correct ITN usage appears to be
a special property of the anti-saliva Ab response which is short-
lived in the absence of ongoing antigenic stimulation, at all ages
[30,36,47]. The response does not seem to build up but wanes
rapidly, when exposure failed. This property represents a major
Figure 3. Changes in anti-gSG6-P1 IgG levels before and after the introduction of ITNs according to age group. Median anti-gSG6-P1
IgG levels in 2005–2006 are presented according to three age groups (A): 0–6 years-old (solid line; n=49), 7–14 years-old (thick-dotted line; n=34)
and .14 years-old (fine-dotted line; n=25). Individual, short-term changes in specific IgG levels from January (just before) to April (just after ITN
installation), are presented according to age group (0–6 years=B; 7–14 years=C and .14 years=D). The arrow indicates the installation of
Insecticide Treated Nets (ITNs) in February 2006. Statistically significant differences between age groups are indicated for respective months
(*: P,0.05; ***: P,0.0001).
doi:10.1371/journal.pone.0015596.g003
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exposure to mosquito bites, especially for efficacy of vector control.
In addition, using a response threshold (DOD=0.204) combined
with DODITNs - the difference between April (after ITNs) and
January 2006 (before) - makes possible the use of this operational
biomarker large-scale [40]. If the DODITNs value is between -
0.204 and +0.204, no clear difference can be defined. In contrast,
if the individual DODITNs value ,20.204, it could be concluded
with a high level of confidence that this individual is benefiting
from ITN installation. The DODITNs parameter could therefore
provide a measure of ITN efficacy at the individual level. An
individual biomarker would also be relevant at the large-scale,
operational level in the field, e.g. in National Malaria Control
Programs (NMCP), since it is pertinent for the evaluation of short-
term ITN efficacy, as demonstrated in the study (April, 2 months
after ITN installation). Short-term and individual changes in Ab
responses to gSG6-P1 provide a superior biomarker to P. falciparum
parasitaemia, especially in a context of low malaria transmission
and by evaluation of ITN efficacy, only in small sub-sample
(around N=100) from populations receiving ITN (parasitaemia
needing a larger population of the order of N=1000). We have
previously shown the high sensitivity and specificity of the gSG6-
P1 Ab response make it ideal for the evaluation of low-level
exposure to An. gambiae [41] which is relevant in areas where
exposure/transmission is being curtailed by NMCP efforts. In
addition, its evaluation can be performed from blood spots on filter
paper, which is easy and operational to be integrated in NMCP
strategies.
The ITN survey, as previously reported in the studied area [33],
indicated that only 53% of ITNs were being correctly used and
were undamaged after just 4–5 months of use (June/July 2006), as
also observed in several other endemic areas [14]. Because of the
high sensitivity of gSG6-P1, we were able to observe an increase in
specific IgG levels from October 2006 (8 months after ITN
installation). The strong decrease of anti-gSG6-P1 IgG response
was therefore transient after ITN installation and the biomarker
reappeared as correct ITN usage waned and individuals were once
re-exposed to An. gambiae. These results point up the relevance of
this salivary biomarker for the evaluation of short-term efficacy as
well as longer-term monitoring.
The results suggest that this salivary biomarker for Anopheles
exposure could constitute an efficient, reliable and new tool for
evaluating the efficacy of malaria vector control, at both
population and individual levels. Further studies are however
needed to confirm this in other areas and for different vector
control strategies. Finally, this first approach could be similarly
applied to vector-control strategies for other mosquito-borne
diseases such as emergent arbovirus diseases.
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